PT - JOURNAL ARTICLE AU - Nishida, Hiroya AU - Han, Velda X AU - Keating, Brooke A AU - Zyner, Katherine G AU - Gloss, Brian AU - Aryamanesh, Nader AU - Dey, Pinki AU - Marshall, Lee L AU - Tsang, Erica AU - Alshammery, Sarah AU - Lau, Xianzhong AU - Dissanayake, Ruwani AU - Mohammad, Shekeeb AU - Graham, Mark AU - Patel, Shrujna AU - Dale, Russell C TI - Chromatin, transcriptional and immune dysregulation in children with neurodevelopmental regression AID - 10.1101/2025.03.05.25322433 DP - 2025 Jan 01 TA - medRxiv PG - 2025.03.05.25322433 4099 - http://medrxiv.org/content/early/2025/03/06/2025.03.05.25322433.short 4100 - http://medrxiv.org/content/early/2025/03/06/2025.03.05.25322433.full AB - Neurodevelopmental including autistic regression in children is often associated with inconclusive diagnostic investigations, leaving the underlying pathophysiology largely unexplored and poorly understood. To address this, we conducted peripheral blood multi-omics profiling in 15 children with neurodevelopmental regression (median age 9 (4-14) years, 60% males), and 15 healthy controls (median age 12 (7-16) years, 60% males). Our comprehensive analysis included bulk RNA sequencing (8 regression vs. 8 controls), single-cell RNA sequencing (two cohorts of 4 regression vs. 4 controls), bulk proteomics (4 regression vs. 4 controls), and phosphoproteomics (4 regression vs. 4 controls). Despite clinical heterogeneity, we identified convergent pathophysiological processes, including dysregulated pathways in epigenetic pathways (chromatin remodelling, histone modifications, transcription factors) and immune responses, as well as downregulated ribosomal and translational pathways. These disruptions in epigenetic, immune and translational processes may arise from complex genetic and environmental interactions, offering opportunities for therapeutic interventions that specifically target these pathways.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support for the study was granted by the Dale NHMRC Investigator Grant AP1193648, Petre Foundation, Cerebral Palsy Alliance, Bioplatforms Australia, PANS Australia, PANDAS Network and International OCD Foundation. VXH was supported by ExxonMobil NUS Research Scholarship and National University Hospital Singapore (NUHS) Clinician-Scientist Program during the course of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the Sydney Children's Hospitals Network Human Research Ethics Committee (HREC/18/SCHN/227, 2021/ETH00356).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.